The Resolute Integrity Stent System features a novel drug-eluting coronary stent coupled with the MicroTrac delivery system.

According to Medtronic, the stent system has been shown in bench testing and in blinded in vivo physician assessment studies to be significantly more deliverable than the current market-leading alternatives.

The Resolute Integrity drug-eluting stent (DES) combines continuous sinusoid technology with two key elements of the original Resolute DES – the cytostatic antiproliferative drug zotarolimus and the biocompatible BioLinx polymer.

Medtronic Coronary and Peripheral division vice president and general manager Sean Salmon said that the Resolute Integrity Stent System provides superior deliverability and powerful performance for complex daily practice and offers physicians a compelling new treatment option for patients with coronary artery disease.